Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Williams, I. L
Right arrow Articles by Zaman, A. G
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: The management of acute myocardial infarction in patients with diabetes mellitus

Ian L Williams

Department of Cardiology, Guy's, King's and St Thomas' School of Medicine, London, UK, ian.williams{at}kingsch.nhs.uk

Brian Noronha

Department of Cardiology, Guy's, King's and St Thomas' School of Medicine, London, UK

Azfar G Zaman

Department of Cardiology, Freeman Hospital, Newcastle upon Tyne, UK

Diabetic subjects are more likely to experience a myocardial infarction and have worse outcomes compared to non-diabetic subjects. The underlying pathophysiology of the atherosclerotic process is not significantly different in diabetic subjects, but the prothrombotic and procoagulant state with which diabetes is associated is thought to contribute to the higher incidence of and worse prognosis after myocardial infarction. Difficulties of re-establishing vessel patency by thrombolytic or mechanical means contribute to the high morbidity and mortality. The diffuse nature of arterial disease with accompanying metabolic derangement contribute to impaired compensatory mechanisms, increased infarct size and a disproportionately more substantial impairment of left ventricular function. The newer adjuvant antithrombotic and anticoagulant agents have particular roles in management therefore and careful modulation of glucose metabolism in the acute and follow-up phase of an infarct may favourably influence outcome.

Key Words: diabetes mellitus • myocardial infarction • acute management.

References

  • Kannel WB, McGee DL Diabetes and cardiovascular disease. The Framingham study. JAMA 1979;241:2035-8.[Abstract/Free Full Text]
  • Fuller JH, Shipley MJ, Rose G., Jarrett RJ, Keen H. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study. BMJ (Clin Res Ed) 1983;287:867-70.[Abstract/Free Full Text]
  • Haffner SM Coronary heart disease in patients with diabetes. N Engl J Med 2000;342:1040-2.[Free Full Text]
  • Lee KL, Woodlief LH, Topol EJ et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. Circulation 1995;91:1659-68.[Abstract/Free Full Text]
  • Abbott RD, Donahue RP, Kannel WB, Wilson PW The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham Study. JAMA 1988;260:3456-60.[Abstract/Free Full Text]
  • Miettinen H., Lehto S., Salomaa V. et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 1998;21:69-75.[Abstract]
  • Granger CB, Califf RM, Young S. et al. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. J Am Coll Cardiol 1993;21:920-5.[Abstract]
  • Mak KH, Moliterno DJ, Granger CB et al. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1997;30:171-9.[Abstract]
  • Gu K., Cowie CC, Harris MI Diabetes and decline in heart disease mortality in US adults. JAMA 1999;281:1291-7.[Abstract/Free Full Text]
  • Norhammar A., Tenerz A., Nilsson G. et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002;359:2140-4.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kip KE, Faxon DP, Detre KM, Yeh W., Kelsey SF, Currier JW Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1996;94:1818-25.[Abstract/Free Full Text]
  • Cleveland JC, Jr., Meldrum DR, Cain BS, Banerjee A., Harken AH Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited. Circulation 1997;96:2932.[Abstract/Free Full Text]
  • Woodfield SL, Lundergan CF, Reiner JS et al. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol 1996; 28:1661-9.[Abstract]
  • Mahgoub MA, Abd-Elfattah AS Diabetes mellitus and cardiac function. Mol Cell Biochem 1998;180:59-64.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mak KH, Topol EJ Emerging concepts in the management of acute myocardial infarction in patients with diabetes mellitus. J Am Coll Cardiol 2000;35:563-8.[Abstract/Free Full Text]
  • Cabin H. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994;343:311-22.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kondo T., Kubota I., Tachibana H., Yamaki M., Tomoike H. Glibenclamide attenuates peaked T wave in early phase of myocardial ischemia. Cardiovasc Res 1996;31:683-7.[Abstract/Free Full Text]
  • Pfeffer MA, Moye LA, Braunwald E. et al. Selection bias in the use of thrombolytic therapy in acute myocardial infarction. The SAVE Investigators. JAMA 1991;266:528-32.[Abstract/Free Full Text]
  • Barron HV, Bowlby LJ, Breen T. et al. Use of reperfusion therapy for acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2. Circulation 1998;97:1150-6.[Abstract/Free Full Text]
  • Barbash GI, White HD, Modan M., Van de Werf F. Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. J Am Coll Cardiol 1993;22:707-13.[Abstract]
  • Hammoud T., Tanguay JF, Bourassa MG Management of coronary artery disease: therapeutic options in patients with diabetes. J Am Coll Cardiol 2000;36:355-65.[Abstract/Free Full Text]
  • Yusuf S., Zhao F., Mehta SR, Chrolavicius S., Tognoni G., Fox KK Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.[Abstract/Free Full Text]
  • Cohen M., Demers C., Gurfinkel EP et al. Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events. Am J Cardiol 1998;82:19L-24L.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Morrow DA, Antman EM, Tanasijevic M. et al. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy. J Am Coll Cardiol 2000;36:1812-17.[Abstract/Free Full Text]
  • McGuire DK, Emanuelsson H., Granger CB et al. Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators. Eur Heart J 2000;21:1750-8.[Abstract/Free Full Text]
  • Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 1998;338:1488-97.[Abstract/Free Full Text]
  • Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998;339:436-43.[Abstract/Free Full Text]
  • Roffi M., Chew DP, Mukherjee D. et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 2001;104:2767-71.[Abstract/Free Full Text]
  • Oliver MF, Opie LH Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias. Lancet 1994;343:155-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Malmberg K., McGuire DK Diabetes and acute myocardial infarction: the role of insulin therapy. Am Heart J 1999;138:S381-S386.[Web of Science][Medline] [Order article via Infotrieve]
  • Fath-Ordoubadi F., Beatt KJ Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation 1997;96:1152-6.[Abstract/Free Full Text]
  • Diaz R., Paolasso EA, Piegas LS et al. Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group. Circulation 1998;98:2227-34.[Abstract/Free Full Text]
  • Malmberg K., Ryden L., Efendic S. et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995;26:57-65.[Abstract]
  • Younis N., Burnham P., Patwala A., Weston PJ, Vora JP Beta blocker prescribing differences in patients with and without diabetes following a first myocardial infarction. Diabet Med 2001;18:159-61.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Opie LH, Thomas M. Propranolol and experimental myocardial infarction: substrate effects. Postgrad Med J 1976;52(suppl 4): 124-32.[Web of Science][Medline] [Order article via Infotrieve]
  • Kjekshus J. Heart rate reduction--a mechanism of benefit? Eur Heart J 1987;8(suppl L):115-22.[CrossRef][Medline] [Order article via Infotrieve]
  • Malmberg K., Norhammar A., Wedel H., Ryden L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation 1999;99:2626-32.[Abstract/Free Full Text]
  • Thomas K., Ottervanger JP, de Boer MJ, Suryapranata H., Hoorntje JC, Zijlstra F. Primary angioplasty compared with thrombolysis in acute myocardial infarction in diabetic patients. Diabetes Care 1999;22:647-9.[Web of Science][Medline] [Order article via Infotrieve]
  • Elezi S., Kastrati A., Pache J. et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998;32:1866-73.[Abstract/Free Full Text]
  • Van Belle E., Abolmaali K., Bauters C., McFadden EP, Lablanche JM, Bertrand ME Restenosis, late vessel occlusion and left ventricular function six months after balloon angioplasty in diabetic patients. J Am Coll Cardiol 1999;34:476-85.[Abstract/Free Full Text]
  • Silva JA, Ramee SR, White CJ et al. Primary stenting in acute myocardial infarction: influence of diabetes mellitus in angiographic results and clinical outcome. Am Heart J 1999;138:446-55.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Wallentin L., Lagerqvist B., Husted S., Kontny F., Stahle E., Swahn E. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease. Lancet 2000;356:9-16.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Boden WE, O'Rourke RA, Crawford MH et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs NonQ-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med 1998;338:1785-92.[Abstract/Free Full Text]
  • Solomon DH, Stone PH, Glynn RJ et al. Use of risk stratification to identify patients with unstable angina likeliest to benefit from an invasive versus conservative management strategy. J Am Coll Cardiol 2001;38:969-76.[Abstract/Free Full Text]
  • Stone GW, Grines CL, Cox DA et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-66.[Abstract/Free Full Text]
  • Chan AW, Moliterno DJ Defining the role of abciximab for acute coronary syndromes: lessons from CADILLAC, ADMIRAL, GUSTO IV, GUSTO V, and TARGET. Curr Opin Cardiol 2001;16:375-83.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Montalescot G., Barragan P., Wittenberg O. et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-903.[Abstract/Free Full Text]
  • Montalescot G., Barragan P., Wittenberg O. et al. Abciximab reduces clinical restenosis in diabetic patients undergoing primary stenting for acute myocardial infarction (The ADMIRAL study). Circulation 2001;104:386.[Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 3, No. 5, 319-324 (2003)
DOI: 10.1177/14746514030030050201
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 British Journal of Diabetes & Vascular DiseaseHome page
S. Sulfi and A. D Timmis
Review: Heart failure complicating acute myocardial infarction in patients with diabetes: pathophysiology and management strategies
The British Journal of Diabetes & Vascular Disease, September 1, 2006; 6(5): 191 - 196.
[Abstract] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Williams, I. L
Right arrow Articles by Zaman, A. G
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?